Patients with higher IL-6 levels have more rapid progression and a higher complication rate so it was proposed that the levels of IL-6 may be used as a biomarker to help assist clinicians in recognizing patients with severe COVID‐19 early in the disease course [11, 12]. This evidence concerns the gene IL6 and COVID-19.